Article Abstract

Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study

Authors: Millie Das, Heather Wakelee


Since the discovery of the critical role played by angiogenesis in tumor growth and development (1), there has been increased interest in evaluating anti-angiogenic agents in the treatment of various malignancies, including non-small-cell lung cancer (NSCLC). Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) and is approved for use in combination with chemotherapy in multiple countries for the treatment of patients with metastatic NSCLC.